Loading…
GKB Ophthalmics (GKB)₹59.46−5.60%Medical Equipment & Supplies
In the Jun 2026 quarter (consolidated), GKB Ophthalmics reported sales of ₹33.11 Cr, up 2.3% from Jun 2025, and net profit of ₹1.84 Cr. For the year to Mar 2026, sales were ₹149 Cr and net profit ₹2.99 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 20.45 | 24.08 | 21.61 | 26.07 | 26.18 | 25.85 | 31.10 | 32.36 | 30.20 | 56.93 | 29.86 | 33.11 |
| Expenses | 20.70 | 24.65 | 21.57 | 24.97 | 26.22 | 26.76 | 33.87 | 31.52 | 27.14 | 55.12 | 26.73 | 30.44 |
| Operating Profit | −0.28 | −0.61 | 0.00 | 1.03 | −0.05 | −0.93 | −2.85 | 0.79 | 3.01 | 1.65 | 3.07 | 2.62 |
| OPM % | −1.4% | −2.6% | 0.0% | 4.0% | −0.2% | −3.6% | −9.2% | 2.5% | 10.1% | 2.9% | 10.4% | 8.0% |
| Other Income | 0.30 | 0.34 | 0.59 | 0.27 | 0.27 | 0.47 | 0.34 | 0.20 | 0.36 | 0.56 | −0.67 | 0.72 |
| Interest | 0.45 | 0.43 | 0.58 | 0.54 | 0.56 | 0.62 | 0.64 | 0.76 | 0.67 | 0.74 | 0.51 | 0.52 |
| Depreciation | 0.72 | 0.72 | 0.71 | 0.75 | 0.76 | 0.76 | 0.79 | 0.79 | 0.81 | 0.81 | 0.79 | 0.79 |
| Profit before tax | −1.16 | −1.43 | −0.68 | 0.00 | −1.09 | −1.85 | −3.92 | −0.55 | 1.90 | 0.67 | 1.07 | 2.04 |
| Tax % | 0.0% | 0.0% | 30.4% | 600.0% | 5.5% | 2.7% | 4.8% | 14.3% | 3.7% | −4.4% | −3.7% | 9.7% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −1.01 | 0.00 |
| Net Profit | −1.18 | −1.43 | −0.88 | 0.10 | −1.14 | −1.90 | −4.12 | −0.63 | 1.83 | 0.69 | 1.11 | 1.84 |
| EPS (Rs) | −2.31 | −2.47 | −1.80 | −0.49 | −2.41 | −4.02 | −7.02 | −2.01 | 3.16 | 0.86 | 0.37 | 1.99 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 44.07 | 76.20 | 78.12 | 57.10 | 59.09 | 57.11 | 71.12 | 75.09 | 88.21 | 109 | 149 | 150 |
| Expenses | 43.98 | 75.05 | 77.03 | 56.02 | 56.02 | 54.98 | 65.99 | 72.03 | 88.01 | 112 | 140 | 139 |
| Operating Profit | −0.99 | 1.99 | 0.99 | 0.99 | 1.99 | 1.99 | 4.99 | 3.98 | 0.99 | −2.99 | 8.97 | 10.35 |
| OPM % | −1.6% | 2.5% | 1.7% | 2.0% | 3.6% | 4.0% | 7.1% | 4.9% | 0.6% | −2.5% | 6.1% | 6.9% |
| Other Income | 11.98 | 3.99 | 0.00 | 1.99 | 0.99 | 1.99 | 0.99 | 0.99 | 1.99 | 1.99 | 0.00 | 0.97 |
| Interest | 1.99 | 0.99 | 0.99 | 1.01 | 0.99 | 2.01 | 0.99 | 1.99 | 2.01 | 2.01 | 2.99 | 2.44 |
| Depreciation | 0.99 | 0.99 | 1.99 | 3.99 | 3.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 3.20 |
| Profit before tax | 7.97 | 2.99 | −0.99 | −1.99 | −1.99 | −0.99 | 1.99 | 0.00 | −2.99 | −6.97 | 2.99 | 5.68 |
| Tax % | 50.0% | 12.0% | −15.0% | −30.0% | 0.0% | −19.0% | 0.0% | 14.0% | 8.0% | 5.0% | 2.0% | — |
| Exceptional items | 6.02 | 2.01 | 0.00 | 1.01 | 0.00 | −1.01 | 0.00 | 0.00 | 0.00 | 0.00 | −2.01 | −1.01 |
| Net Profit | 3.99 | 2.99 | −0.99 | −0.99 | −1.99 | −0.99 | 1.99 | 0.00 | −2.99 | −6.99 | 2.99 | 5.47 |
| EPS (Rs) | 9.48 | 6.23 | −2.33 | −2.36 | −3.64 | −1.80 | 2.51 | −0.33 | −5.56 | −13.94 | 2.21 | 6.38 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.00 | 4.01 | 4.01 | 4.01 | 5.00 | 5.00 | 5.01 | 5.01 | 5.01 | 5.01 | 5.00 | 5.00 |
| Reserves | 36.00 | 41.04 | 43.05 | 41.04 | 50.02 | 53.99 | 58.02 | 58.00 | 58.05 | 55.03 | 46.91 | 47.95 |
| Borrowings | 9.00 | 7.01 | 7.01 | 10.01 | 14.01 | 15.01 | 12.01 | 12.02 | 11.02 | 11.01 | 14.00 | 11.99 |
| Other Liabilities | 26.12 | 17.08 | 28.13 | 28.13 | 25.13 | 28.14 | 32.15 | 35.16 | 38.17 | 43.20 | 59.28 | 68.32 |
| Total Liabilities | 75.12 | 69.14 | 82.20 | 83.19 | 94.16 | 102 | 107 | 110 | 112 | 114 | 125 | 132 |
| Fixed Assets | 11.99 | 12.98 | 17.99 | 17.99 | 25.96 | 25.97 | 23.97 | 22.97 | 18.97 | 17.98 | 16.97 | 14.98 |
| CWIP | 1.01 | 1.01 | 1.01 | 0.00 | 0.00 | 0.00 | 1.01 | 3.01 | 4.01 | 4.01 | 4.01 | 4.01 |
| Investments | 16.03 | 10.02 | 3.01 | 0.00 | 1.01 | 1.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 |
| Other Assets | 46.09 | 46.13 | 60.19 | 64.20 | 68.19 | 75.16 | 80.20 | 82.20 | 87.26 | 91.25 | 102 | 111 |
| Inventories | 20.95 | 20.93 | 30.94 | 31.90 | 27.95 | 30.91 | 34.90 | 37.93 | 38.87 | 39.90 | 49.90 | 54.90 |
| Trade receivables | 17.96 | 16.97 | 24.95 | 26.92 | 23.96 | 24.94 | 18.95 | 19.96 | 27.96 | 27.96 | 24.93 | 44.92 |
| Cash & equivalents | 3.01 | 4.01 | 3.01 | 3.01 | 10.01 | 14.02 | 17.02 | 16.02 | 14.02 | 18.01 | 14.01 | 5.01 |
| Total Assets | 75.12 | 69.14 | 82.20 | 83.19 | 94.16 | 102 | 107 | 110 | 112 | 114 | 125 | 132 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 6.99 | −10.98 | −2.99 | −2.99 | 3.99 | 2.99 | 6.99 | 4.99 | −2.99 | 3.99 | −2.99 | −3.99 |
| Cash from investing activity | 0.00 | 14.94 | 3.99 | 0.99 | −9.96 | −3.98 | −16.93 | −3.98 | 0.99 | −1.99 | 2.99 | 8.96 |
| Cash from financing activity | −5.99 | −2.99 | −0.99 | 0.99 | 12.99 | 3.99 | 2.99 | −1.99 | −1.99 | −1.99 | 0.99 | −5.99 |
| Net cash flow | 1.01 | 0.00 | −1.01 | 0.00 | 7.02 | 4.02 | −7.02 | 0.00 | −4.02 | 1.01 | 0.00 | 0.00 |
| Capex | 0.67 | 3.17 | 6.33 | 1.89 | 13.22 | 3.87 | 6.34 | 4.77 | 1.22 | 2.09 | 2.16 | 1.04 |
| Free cash flow | 7.02 | −13.03 | −9.03 | −5.02 | −6.01 | 0.00 | 1.01 | 0.00 | −2.01 | 2.01 | −6.01 | −5.02 |
| CFO / OP % | 1,117.0% | 639.0% | −112.0% | −190.0% | 346.0% | 154.0% | 300.0% | 105.0% | −71.0% | 865.1% | 118.0% | −41.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 191 | 143 | 118 | 129 | 150 | 155 | 125 | 100 | 134 | 117 | 85 | 110 |
| Inventory days | 423 | 284 | 224 | 222 | 288 | 300 | 348 | 306 | 297 | 244 | 249 | 188 |
| Days payable | 344 | 157 | 170 | 169 | 218 | 235 | 235 | 209 | 184 | 203 | 196 | 196 |
| Cash conversion cycle | 271 | 272 | 174 | 184 | 222 | 223 | 239 | 199 | 249 | 160 | 141 | 104 |
| Working capital days | 97 | 156 | 111 | 115 | 110 | 110 | 117 | 105 | 135 | 97 | 78 | 78 |
| ROCE % | 0.0% | −1.0% | 3.0% | 0.0% | −2.0% | −1.0% | 3.0% | 4.0% | 2.0% | −1.0% | −6.0% | 10.9% |
For the Jun 2026 quarter, GKB Ophthalmics reported sales of ₹33.11 Cr, up 2.3% year on year and net profit of ₹1.84 Cr. The operating margin was 8.0%.
GKB Ophthalmics' sales for the year to Mar 2026 were ₹149 Cr; over the last twelve months they were ₹150 Cr.
Net profit for the year to Mar 2026 was ₹2.99 Cr, and ₹5.47 Cr over the last twelve months. Earnings per share over the same trailing period were ₹6.38.
GKB Ophthalmics reported borrowings of ₹11.99 Cr at Mar 2026, against cash and equivalents of ₹5.01 Cr.
Cash from operations was −₹3.99 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹5.02 Cr.